University of Washington Prostate Cancer Clinical Trials Consortium Application
Annual rept. 1 Apr 2010-31 Mar 2011
WASHINGTON UNIV SEATTLE
Pagination or Media Count:
Purpose Maintain active and productive status as a member of the Prostate Cancer Clinical Trails Consortium throughout the funding period. Scope Since the annual report of April 2010, the University of Washington continues to be an active contributing member of the PCCTC, fulfilling goals set forth in the Statement of Work. Major Progress This last year, we opened 3 trials, and introduced 3 Letters of Intent LOIs to the Consortium. We are opening 5 additional therapeutic trials and have agreed to participate in 2 additional trails. We enrolled 42 patients on therapeutic trials and 7 patients on Consortium biomarker validation phase 3 trials. We are authors on 9 Consortium abstracts, and 2 manuscripts, all abstracts presented or to be presented at ASCO, AUA, GU ASCO. An active plan to recruit minoritydisproportionately affected populations is a high priority and therefore in constant evolution. Our recruitment in this area matches the regional proportion of these populations. Results We continue to develop and grow our infrastructure that supports active, productive Consortium participation and which has enabled us to reach the stated goals for patient accrual and LOI proposals. Significance The Consortium provides a mechanism for participation in early clinical development of novel agents and rapid testing of these agents for the treatment of prostate cancer. At our institution, our scientificSPOREPCF Challenge grant and Consortium clinical research goals are complementary. Validation of biomarkers is of great significance for shortening the time to drug approval and availability of new agents to patients with prostate cancer.
- Medicine and Medical Research